Literature DB >> 28225333

Why do clinical trials of Xpert® MTB/RIF fail to show an effect on patient relevant outcomes?

T H Boyles1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28225333     DOI： 10.5588/ijtld.16.0801

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN： 1027-3719            Impact factor:   2.373


× No keyword cloud information.
  7 in total

1.  Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  David J Horne; Mikashmi Kohli; Jerry S Zifodya; Ian Schiller; Nandini Dendukuri; Deanna Tollefson; Samuel G Schumacher; Eleanor A Ochodo; Madhukar Pai; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2019-06-07

2.  Performance of Xpert MTB/RIF, Xpert Ultra, and Abbott RealTime MTB for Diagnosis of Pulmonary Tuberculosis in a High-HIV-Burden Setting.

Authors:  Wendy Stevens; Lesley Scott; Rebecca H Berhanu; Anura David; Pedro da Silva; Kate Shearer; Ian Sanne
Journal:  J Clin Microbiol       Date:  2018-11-27       Impact factor: 5.948

3.  Impact of GxAlert on the management of rifampicin-resistant tuberculosis patients, Port Moresby, Papua New Guinea.

Authors:  J K Banamu; E Lavu; K Johnson; R Moke; S S Majumdar; K C Takarinda; R J Commons
Journal:  Public Health Action       Date:  2019-09-21

4.  Discovery and Validation of a Six-Marker Serum Protein Signature for the Diagnosis of Active Pulmonary Tuberculosis.

Authors:  Mary A De Groote; David G Sterling; Thomas Hraha; Theresa M Russell; Louis S Green; Kirsten Wall; Stephan Kraemer; Rachel Ostroff; Nebojsa Janjic; Urs A Ochsner
Journal:  J Clin Microbiol       Date:  2017-08-09       Impact factor: 5.948

5.  Impact of the diagnostic test Xpert MTB/RIF on patient outcomes for tuberculosis.

Authors:  Frederick Haraka; Mwaka Kakolwa; Samuel G Schumacher; Ruvandhi R Nathavitharana; Claudia M Denkinger; Sebastien Gagneux; Klaus Reither; Amanda Ross
Journal:  Cochrane Database Syst Rev       Date:  2021-05-06

6.  Rational use of Xpert testing in patients with presumptive TB: clinicians should be encouraged to use the test-treat threshold.

Authors:  Tom Decroo; Aquiles R Henríquez-Trujillo; Anja De Weggheleire; Lutgarde Lynen
Journal:  BMC Infect Dis       Date:  2017-10-11       Impact factor: 3.090

7.  A prospective study evaluating the impact of cartridge-based nucleic acid amplification test (CBNAAT) on the management of tuberculosis in a low-resource high-burden Indian rural setting.

Authors:  Jonathan Youngs; Sushil Patil; Yogesh Jain
Journal:  J Family Med Prim Care       Date:  2018 Sep-Oct
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.